Quick Answer
Moderna, Inc. reported Research And Development Expense of $3.13 billion for the year ending 2025.
- Moderna, Inc. showed a decrease of -31.1% in Research And Development Expense from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $90.12 million | Q2 2018: $104.48 million | Q3 2018: $109.05 million | Q1 2019: $130.41 million | Q2 2019: $128.31 million | Q3 2019: $119.64 million | Q1 2020: $115.00 million | Q2 2020: $152.00 million | Q3 2020: $344.00 million | Q1 2021: $401.00 million | Q2 2021: $421.00 million | Q3 2021: $521.00 million | Q1 2022: $554.00 million | Q2 2022: $710.00 million | Q3 2022: $820.00 million | Q1 2023: $1.13 billion | Q2 2023: $1.15 billion | Q3 2023: $1.16 billion | Q1 2024: $1.06 billion | Q2 2024: $1.22 billion | Q3 2024: $1.14 billion | Q1 2025: $856.00 million | Q2 2025: $700.00 million | Q3 2025: $801.00 million.
- Over the full 10 years of available data (2016 to 2025), Moderna, Inc.'s Research And Development Expense has grown by 1,040.1%.
- Historical annual values: Fiscal year 2025: $3.13 billion | Fiscal year 2024: $4.54 billion | Fiscal year 2023: $4.85 billion | Fiscal year 2022: $3.30 billion | Fiscal year 2021: $1.99 billion | Fiscal year 2020: $1.37 billion | Fiscal year 2019: $496.00 million | Fiscal year 2018: $454.08 million | Fiscal year 2017: $410.46 million | Fiscal year 2016: $274.72 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: